EUVIMEDEUVIMED entdecken
Crossref

Targeting InhA in drug-resistant Mycobacterium tuberculosis: potent antimycobacterial activity of diaryl ether dehydrozingerone derivatives

Mohamad Mosa Mubarak, Hadiya Amin Kantroo, Firdoous Ahmad Mir, Chetan Kumar, Zahoor Ahmad

Archives of Microbiology · 2025

DOI: 10.1007/s00203-025-04238-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Microbiology, 2025. Verfasst von Mohamad Mosa Mubarak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Microbiology and PK-PD Division, CSIR-Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, J&K, 190005, India. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Antitubercular Agents, Bacterial Proteins, Oxidoreductases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB) remains a major global threat, with 10 million new cases and 1.5 million deaths each year. In multidrug-resistant tuberculosis (MDR-TB), resistance is most commonly observed against isoniazid (INH) and rifampicin (RIF), the two frontline drugs. Isoniazid resistance is predominantly linked to mutations in the InhA gene, which encodes an enzyme involved in mycolic acid synthesis, a vital component of the mycobacterial cell wall. Mutations in InhA reduce drug binding, rendering INH ineffective. These morbidity and mortality figures, along with the fact that the rise and global spread of drug-resistant TB, underscores the need for the discovery of novel therapeutics. In this direction, we have previously synthesized, characterized, and screened a library of diaryl ether dehydrozingerone derivatives against mycobacteria and identified two best hits, 7 and 14, based on bacteriostatic activities. The present study aimed to thoroughly investigate the antituberculosis potential of these compounds, particularly regarding drug-resistant TB. Our findings revealed that both compounds exhibited tuberculocidal activity against the standard laboratory strain Mycobacterium tuberculosis (M. tb) H37Rv, with minimal bactericidal concentrations (MBC) of 4μg/ml for compound 7 and 8 μg/ml for compound 14. Next, concentration vs time-kill kinetics of both these compounds showed concentration-dependent bactericidal activities against M. tb and complete pathogen eradication from culture at just 16× MIC. Both compounds were found to be suitable for combination regimens as their interactions with isoniazid and rifampicin against M. tb were observed to be synergistic. Additionally, 7 and 14 exhibited minimal hemolysis against human RBCs and less cytotoxicity was observed against three human cell lines up to 1000 μM. Molecular docking revealed that these compounds bind more effectively to M. tb InhA, including its mutant forms where isoniazid binding is impaired, outperforming both isoniazid and triclosan in binding affinity. Importantly 7 and 14 showed potent activity against drug-susceptible clinical isolates and two isoniazid-resistant M. tb clinical isolates equivalent to that against M. tb H37Rv. The most interesting observation was that both compounds were found to be effective against three multi-drug resistant (MDR) strains of M. tb, thereby depicting their potential against drug-resistant TB. An ex vivo assay on RAW 264 cells infected with M. tb demonstrated a significant reduction in bacterial load at 8× MIC, revealing the fact that these compounds are highly effective against intracellular M. tb H37Rv. To the best of our knowledge, this is the first study that reports promising antimycobacterial potential of 7 and 14 against drug-susceptible, isoniazid-resistant, and MDR tuberculosis which warrants further exploration considering the need for new anti-TB medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisAntitubercular AgentsBacterial ProteinsOxidoreductasesMicrobial Sensitivity TestsHumansTuberculosis, Multidrug-ResistantIsoniazidMolecular Docking SimulationRifampinDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

Antituberculosis potentialDiaryl ether dehydrozingerone derivativesIsoniazid resistanceMultidrug-resistantMycobacterium tuberculosisTuberculosis

Substanzen

Antitubercular AgentsInhA protein, MycobacteriumBacterial ProteinsOxidoreductasesIsoniazidRifampin

Autor:innen und Institutionen

  • Clinical Microbiology and PK-PD Division, CSIR-Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, J&K, 190005, India.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India.
  • Genetics Resources and Agrotechnology Division, CSIR-Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, J&K, 190005, India.
  • School of Pharmaceutical and Populations Health Informatics, DIT University, Dehradun, 248009, India. chetan.kumar@dituniversity.edu.in.
  • Clinical Microbiology and PK-PD Division, CSIR-Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, J&K, 190005, India. zahoorap@iiim.res.in.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India. zahoorap@iiim.res.in.

Förderung

  • Department of Biotechnology, Ministry of Science and Technology, India
  • Indian Council of Medical Research

Zitieren

APA

Mubarak, M. M., Kantroo, H. A., Mir, F. A., Kumar, C., & Ahmad, Z. (2025). Targeting InhA in drug-resistant Mycobacterium tuberculosis: potent antimycobacterial activity of diaryl ether dehydrozingerone derivatives. Archives of Microbiology. https://doi.org/10.1007/s00203-025-04238-x

Vancouver

Mubarak MM, Kantroo HA, Mir FA, Kumar C, Ahmad Z. Targeting InhA in drug-resistant Mycobacterium tuberculosis: potent antimycobacterial activity of diaryl ether dehydrozingerone derivatives. Archives of Microbiology. 2025. doi:10.1007/s00203-025-04238-x

BibTeX
@article{Mubarak2025,
  author = {Mubarak, Mohamad Mosa and Kantroo, Hadiya Amin and Mir, Firdoous Ahmad and Kumar, Chetan and Ahmad, Zahoor},
  title = {Targeting InhA in drug-resistant Mycobacterium tuberculosis: potent antimycobacterial activity of diaryl ether dehydrozingerone derivatives},
  journal = {Archives of Microbiology},
  year = {2025},
  doi = {10.1007/s00203-025-04238-x}
}
Kostenlos starten →